Article written by Robert Sanders, UC Berkeley
Photo
Berkeley Optometry Professor John Flannery in his lab at the Helen Wills Neuroscience Institute on the UC Berkeley campus.
The researchers say that, within as little as three years, the gene therapy — delivered via an inactivated virus — could be tried in humans who’ve lost sight because of retinal degeneration, ideally giving them enough vision to move around and potentially restoring their ability to read or watch video.
Read More on the Berkeley News Page